Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 05, 2022 09:07 ET | Source: Aravive, Inc.

Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer

HOUSTON, July 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
June 03, 2022 07:00 ET | Source: Aravive, Inc.

Aravive Appoints Rudy Howard as Chief Financial Officer

HOUSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
May 26, 2022 17:11 ET | Source: Aravive, Inc.

Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)

Abstract selected for oral discussion on Genitourinary Cancer on Saturday, June 4, 2022Development of biomarker offers the potential of a first in class targeted therapy in renal cancerCompany has a...
May 17, 2022 07:00 ET | Source: Aravive, Inc.

Aravive to Participate in H.C. Wainwright Global Investment Conference

HOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail...
May 12, 2022 07:00 ET | Source: Aravive, Inc.

Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates

Reported positive updated data and new biomarker data from Phase 1b Study of Batiraxcept in ccRCCPresented updated modeling data from batiraxcept clinical trials at the AACR annual meeting Dosed...
May 05, 2022 07:00 ET | Source: Aravive, Inc.

Aravive to Host Key Opinion Leader Symposium on May 11, 2022

HOUSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that it...
April 29, 2022 07:00 ET | Source: Aravive, Inc.

Aravive Announces Poster Presentations at the 2022 ASCO Annual Meeting

HOUSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the...
April 01, 2022 07:00 ET | Source: Aravive, Inc.

Aravive Announces Closing of $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

HOUSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that it has...
March 31, 2022 16:05 ET | Source: Aravive, Inc.

Aravive Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates

Reported positive data from Phase 1b trials of batiraxcept in clear cell renal cell carcinoma and pancreatic adenocarcinoma in 1Q’22; on track to report updated data in 2Q’22Dosed first patient in...
March 30, 2022 08:00 ET | Source: Aravive, Inc.

Aravive Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

HOUSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced today that it...